Published trial adds weight to Takeda's confidence in next-generation antidiabetic
This article was originally published in Scrip
Executive Summary
The first full results to be published from a Phase II trial with Takeda's first-in-class oral antidiabetic TAK-875 confirm both efficacy benefits for the GPR40 agonist and a significantly lower incidence of hypoglycaemia compared with the sulphonylurea glimepiride.